ProQR Therapeutics NV

As of November 4, 2021, ProQR Therapeutics NV is considered risky and overvalued, with key financial metrics indicating challenges in profitability, despite a strong 3-year return of 192% that has been overshadowed by a year-to-date decline of 17.36%.

As of November 4, 2021, ProQR Therapeutics NV is considered overvalued and classified as "risky" due to negative financial metrics, including a P/E ratio of -6.2227, despite a recent monthly stock return of 16.77% and a year-to-date decline of 26.42%.

As of May 12, 2025, the market trend is mildly bearish, indicated by daily moving averages and monthly MACD signals, despite some counterbalance from weekly indicators.

As of March 2022, the management team of ProQR Therapeutics NV includes Mr. Dinko Valerio (Chairman) and five independent members: Mr. Bart Filius, Ms. Theresa Heggie, Ms. Alison Lawton, M. Antoine Papiernik, and Dr. James Shannon, who oversee the company's strategic direction and governance.

ProQR Therapeutics N.V. is a pre-clinical biopharmaceutical company focused on developing RNA-based therapies for severe genetic disorders. As of March 2025, it has a market cap of $205.86 million, with net sales of $5 million and a net loss of $11 million.

As of Jun 18, ProQR Therapeutics NV has a market capitalization of 205.86 million, with net sales of 20.36 million and a net profit of -32.35 million over the latest four quarters. The company reported shareholder's funds of 91.70 million and total assets of 173.92 million as of Dec 24.